IL18 and COVID-19: These subsets expressed the amphiregulin (AREG), epiregulin (EREG), and cytokine interleukin-18 (IL-18) genes and appeared to exhibit profibrogenic and proinflammatory features [50], suggesting that they may be potential targets for COVID-19 treatment.